words lines 0 60 0 20 top 50% bottom top 1 0 0 .22 back 1 0 .001 1 .1 1.5 none top bottom center center true 1 none top top center top true 0 200 .001 none
top bottom top center true 1 none top bottom bottom bottom true 1 none

Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022

Dec 27, 2022

Juniper Biologics

Author

We’re proud to announce that we’ve won Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022, in recognition of our licensing deal for TG-C LD ! This acquisition was our first step in ensuring patients suffering from osteoarthritis receive the treatment they need and have the quality of life they deserve. 

Juniper Biologics (2022 Winner: M&A Awards) – Acquisition International (acquisition-international.com)

APAC INSIDER
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
M&A Awards 2023
Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023
1703238629922
Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore
Follow us on Facebook